A Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1)

Recruiting

18 years - 99 years

Male

Phase N/A

1 Location

Brief description of study

This study involves research and is conducted to determine the safety, tolerability (how 6 your body reacts to the drug) and effectiveness of a study drug called REGN5678 which 7 will be given alone first and then be given in combination with cemiplimab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Prostate Cancer
Age: 18 years - 99 years
Gender: Male

Males, aged 18 or older, diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma.

Updated on 04 Aug 2024. Study ID: 849839

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Prostate Cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study